Related references
Note: Only part of the references are listed.Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells
Laween Uthman et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
Kai Jiang et al.
PROTEIN & CELL (2022)
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
Soraya Puglisi et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Yu Jin Chung et al.
CARDIOVASCULAR RESEARCH (2021)
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Sean Kang et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Valentina Spigoni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Full length article Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B
Sadaf Riaz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Empagliflozin inhibits Na+/H+exchanger activity in human atrial cardiomyocytes
Maximilian Trum et al.
ESC HEART FAILURE (2020)
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity
Akira Yoshii et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Diabetic Cardiomyopathy Definition, Diagnosis, and Therapeutic Implications
Stefania Paolillo et al.
HEART FAILURE CLINICS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
Oriol Iborra-Egea et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Na+/H+ exchanger isoform 1-induced osteopontin expression facilitates cardiac hypertrophy through p90 ribosomal S6 kinase
Nabeel Abdulrahman et al.
PHYSIOLOGICAL GENOMICS (2018)
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman et al.
FRONTIERS IN PHYSIOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart
Anne Van Steenbergen et al.
SCIENTIFIC REPORTS (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Cardiac hypertrophy reduction in SHR by specific silencing of myocardial Na+/H+ exchanger
Mariela B. Nolly et al.
JOURNAL OF APPLIED PHYSIOLOGY (2015)
Na+/H+ exchanger isoform 1 induced osteopontin expression in cardiomyocytes involves NFAT3/Gata4
Mohamed Mlih et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Na+/H+ Exchanger Isoform 1 Induced Cardiomyocyte Hypertrophy Involves Activation of p90 Ribosomal S6 Kinase
Maiy Jaballah et al.
PLOS ONE (2015)
Diabetes mellitus: The epidemic of the century
Akram T. Kharroubi et al.
WORLD JOURNAL OF DIABETES (2015)
Global estimates of diabetes prevalence for 2013 and projections for 2035
L. Guariguata et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy
Q-Q. Wu et al.
HERZ (2014)
NHE-1: Still a viable therapeutic target
Morris Karmazyn
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent
Sarah J. Watkins et al.
HYPERTENSION RESEARCH (2012)
The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro
Sarah J. Watkins et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2011)
Diagnosis and Classification of Diabetes Mellitus
DIABETES CARE (2010)
Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy
Jin Xue et al.
PHYSIOLOGICAL GENOMICS (2010)
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
Sanjay K. Banerjee et al.
CARDIOVASCULAR RESEARCH (2009)
Share Paper
